Table I.
Selected features of systemic sclerosis patients studied*.
| lcSSc 1 | lcSSc 2 | lcSSc 3 | dcSSc 1 | dcSSc 2 | dcSSc 3 | |
|---|---|---|---|---|---|---|
| Age | 58 | 49 | 43 | 60 | 32 | 61 |
| Sex | F | F | F | F | F | F |
| Disease Duration, (years)† | 4 | 2 | 1 | 1 | 1 | 2 |
| Extent of maximal skin induration,‡ | 3% | 2% | 2% | 27% | 30% | 35% |
| mRSS | 7 | 4 | 5 | 25 | 26 | 28 |
| Organ Involvement | ||||||
| Raynaud’s Phenomenon | YES | YES | YES | YES | YES | YES |
| G-I | YES | NO | YES | YES | NO | YES |
| Pulmonary | NO | NO | NO | NO | YES | YES |
| Cardiac | NO | NO | NO | NO | NO | NO |
| Renal | NO | NO | NO | NO | NO | NO |
| ANA Test | ||||||
| ANATiter | 1:640 | 1:320 | 1:5120 | 1:2560 | 1:360 | 1:640 |
| Scl-70 | NEG | NEG | NEG | NEG | POS | POS |
| ACA | POS | POS | POS | NEG | NEG | NEG |
| Treatment | ||||||
| Antifibrotic | NO | NO | NO | D-Pen | D-Pen | D-Pen |
| Immunosupressive | NO | NO | NO | NO | NO | NO |
*
lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous SSc.
†
Determined from onset of skin induration or first non-Raynaud’s phenomenon manifestation.
‡
Extent of affected body surface (% of total body surface). mRSS: modified Rodman Skin Score.
D-Pen: D-penicillamine.